Establishing Best Treatment Strategy for T4 Esophageal Cancer

Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-70
SponsorNational Cheng-Kung University Hospital

About this trial

The goal of this clinical trial is to investigate the safety and efficacy of a new treatment approach for T4-stage esophageal cancer, which involves chemoradiotherapy after induction chemotherapy. The main questions it aims to answer are:

* Does the new induction chemotherapy followed by chemoradiation reduce esophageal perforation rate? * Does the new induction chemotherapy followed by chemoradiation increase treatment response rate and patient survival? Researchers will analyze the above data to see if the new treatment approach works to treat T4 esophageal cancer.

Participants will:

* Receive induction chemotherapy for 4 to 8 cycles, followed by chemoradiation therapy if downstage to T3 * Visit the clinic once every week for checkups and tests * Keep a diary of their symptoms

Eligibility criteria

Qualifiers

Histologically confirmed esophageal squamous cell carcinoma

Tumor or lymph nodes invade adjacent organs (T4 stage)

Aged between 18-70 years old

Patient health status score Eastern Cooperative Oncology Group (ECOG) performance status (PS) <2

Disqualifiers

Previous chemotherapy history

Myocardial infarction within the last three months

History of unstable angina, interstitial pneumonia, fibrotic lung disease, or severe emphysema

Has other malignancies currently

Trial design

Treatments tested in this trial

  • "Docetaxel", "Cisplatin", "fluorouracil", "Radiation"

Treatment groups

22 Participants
are divided into 1 treatment group